연구업적

연도	2024년	2023년	2022년	2021년	2020년
SCI 논문 발표편수	책임	179편	173편	163편	184편	135편
공동	147편	120편	115편	136편	168편
합계	326편	293편	278편	320편	303편

3187. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial

Soo Yeon Baek, Woo Chul Noh, Sei-Hyun Ahn, Hyun-Ah Kim, Jai Min Ryu, Seung Il Kim, Eun-Gyeong Lee, Seock-Ah Im, Yongsik Jung, Min Ho Park, Kyong Hwa Park, Su Hwan Kang, Joon Jeong, Eunhwa Park, Sung Yong Kim, Min Hyuk Lee, Lee Su Kim, Woosung Lim ; Seonok Kim, MSc18 ; and Hee Jeong Kim, MD, PhD

J Clin Oncol 2023 Nov 1;41(31):4864-4871. Link

3186. Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers

Nikas IP, Lim S, Im S-A, Lee K-H, Lee D-W, Lee H, Ryu HS

Pathobiology 2023 Oct 10. [Epub ahead of print] Link

3185. Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach

Seong-Ho Kong, Yukinori Kurokawa, Jeong-Hwan Yook, Haruhiko Cho, Oh-Kyoung Kwon, Toru Masuzawa, Kyung Hee Lee, Sohei Matsumoto, Young Soo Park, Hiroshi Honda, Seung-Wan Ryu, Takashi Ishikawa, Hye Jin Kang, Kazuhito Nabeshima, Seock-Ah Im, Toshio Shimokawa, Yoon-Koo Kang, Seiichi Hirota, Han-Kwang Yang & Toshirou Nishida

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2023 Sep;26(5):775-787. Link

3184. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Sara M Tolaney, Arlene Chan, Katarina Petrakova , Suzette Delaloge , Mario Campone , Hiroji Iwata, Parvin F Peddi , Peter A Kaufman , Elisabeth De Kermadec , Qianying Liu , Patrick Cohen , Gautier Paux , Lei Wang , Nils Ternès , Eric Boitier , Seock-Ah Im

J Clin Oncol 2023 Aug 20;41(24):4014-4024 Link

3183. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer

Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz , Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios , Aditya Bardia , Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi

Ther Adv Med Oncol 2023 May 29;15:17588359231178125. Link

3182. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer

Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Perna, Junji Tsurutani, Binghe Xu, Erika Hamilton, Seock-Ah Im, Zbigniew Nowecki, Joohyuk Sohn, Michelino De Laurentiis , Noelia Martínez Jañez , Barbara Adamo , Keun Seok Lee , Kyung Hae Jung , Gábor Rubovszky , Ling-Ming Tseng , Yen-Shen Lu , Yuan Yuan , Micah J Maxwell, Vincent Haddad , Sabrina S Khan , Hope S Rugo , Barbara Pistilli

Future Oncol 2023 Jun 30 [Epub ahead of print] Link

3181. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung-Bae Kim, Toshimi Takano, Seock-Ah Im, Giuliano Borges, Joao Paulo Lima, Sercan Aksoy, Joaquin Gavila Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruiz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, Francois P Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Cai Wu, Changan Chu, Anton Egorov, Ian Krop

Lancet 2023 May 27;401(10390):1773-1785. Link

3180. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial

Xavier Pivot, Javier Cortés, Diana Lüftner, Gary H Lyman, Giuseppe Curigliano, Igor M Bondarenko, Jin-Hee Ahn, Seock-Ah Im, Maria Litwiniuk, Yaroslav V Shparyk, Gwo Fuang Ho, Nikolay V Kislov, Marek Wojtukiewicz, Tomasz Sarosiek, Yee Soo Chae, Jin Seok Ahn, Hyerin Jang, Sujung Kim, Jiwon Lee, YeChan Yoon

JAMA Netw Open 2023 Apr 3;6(4):e235822. Link

3179. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial

Elżbieta Senkus, Suzette Delaloge, Susan M Domchek, Pierfranco Conte, Seock-Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark Robson, Nadine Tung

Int J Cancer 2023 Aug 15;153(4):803-814. Link

3178. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Mark E Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, Allison Allen, Pierfranco Conte

Eur J Cancer 2023 Feb 14;184:39-47. Link

최근 5년 연구업적 현황